Enduring Material

Answering the Need for SARS-CoV-2 Guidance Statements
View Activity Info
Enter Basic User Info
Take Post Test
Create Account
Done
View Activity Info
Continue to Enduring Material
 
 
National Psoriasis Foundation

6600 SW 92nd Ave., Suite 300
Portland, OR 97223-7195
General Information
Thursday, September 10, 2020 - Friday, September 10, 2021
National Psoriasis Foundation
Virtual Conference Room
Psound Bytes CME Podcast
National Psoriasis Foundation
Objectives
  • Increased understanding of managing patients with psoriatic disease during the COVID-19 pandemic has increased
  • Have a better understanding of risks to patients with psoriatic disease in relation to COVID-19 infection
Presentations and Speakers
Answering the Need for SARS-CoV-2 Guidance Statements
  • Joel Gelfand, MD
  • Christopher Ritchlin, MD
Available Credits/Points
  • The National Psoriasis Foundation designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
A discussion with COVID-19 Task Force Chairs, dermatologist Dr. Joel Gelfand and rheumatologist Dr. Christopher Ritchlin with guest host Dr. Stacie Bell, Chief Scientific and Medical Officer at the National Psoriasis Foundation.

Given the pandemic and need for clarity the NPF developed a COVID-19 Task Force. Hear Co-Chairs, dermatologist Dr. Joel Gelfand, Director, Psoriasis and Phototherapy Treatment Center at Penn) and rheumatologist Dr. Christopher Ritchlin, Co-Director, Psoriasis Center, University of Rochester Medical Center in New York, discuss the evidence and content of NPF’s 22 guidance statements addressing effects, risks, and best practices for treatment of patients with psoriatic disease.
Disclosure Statements
NPF Staff/Planning Committee, has disclosed no relevant financial relationships with commercial interests.
Speakers:
Joel Gelfand, MD has disclosed a relevant financial relationship with a commercial interest in the last 12 months:
  • Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB, and Sanofi and Pfizer Inc - Consulting
  • Eli Lilly and Company and Ortho Dermatologics - CME work related to psoriasis
  • Society for Investigative Dermatology - deputy editor for the Journal of Investigative Dermatology
  • Abbvie, Janssen, Novartis Corp, Sanofi, Celgene, OrthoDermatologics, and Pfizer Inc -
Christopher Ritchlin, MD has disclosed a relevant financial relationship with a commercial interest in the last 12 months:
  • AbbVie, Amgen, Janssen, Novartis, UCB, Boerhinger Ingelheim -
  • Amgen, UCB and Abbvie -
Accreditation Statement
  • The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Test Information
100 %
9/9/2020
Continue to Enduring Material